Second, Teliso-V plus erlotinib, another EGFR TKI, was evaluated in patients with c-MET-positive NSCLC (confirmed histology [H]-score ≥ 150) [41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.